The Diabetes Market Outlook to 2011

The Diabetes Market Outlook to 2011 provides in-depth insights into new product launches, upcoming patent expiries and on-going clinical trials in order to predict changes in global market dynamics. Key R&D trends are analyzed and pipeline compounds of the top players are evaluated, enabling you to strengthen your position in the diabetes market and anticipate future product success.

The global diabetes market has seen a high level of innovation, particularly in non-invasive methods of insulin delivery such as inhalable, oral and patch technology. These are seen as favorable by patients and should result in an increase in compliance, thus improving glycemic control and leading to a reduction in diabetic complications.

The US has the dominant share of the global diabetes market, with 49.6% of 2005 global sales; this is due mainly to the high prevalence of the condition in the country, its ageing population and the increasing incidence of diabetes associated with Western diets.

Sanofi-Aventis's Lantus is the highest-selling insulin, with sales of $1,490.4m in 2005 and a high growth rate of 47.5%. Lantus's high sales are mainly attributable to its positive effects on lipid profiles and its side effect of weight loss.

Read more...

• Pharma Marketing 2010 (20/07/2010)
• In-licensing need for the Russian market (16/07/2010)
• Long-term pricing & reimbursement strategies to penetrate significant growth markets (09/07/2010)

• Molecular Targeted Cancer Therapies (12/10/2009)
• Top 20 Cancer Therapy Brands (12/10/2009)
• Colorectal Cancer (12/10/2009)
• Community Antibacterials (25/09/2009)
• Vaccine Antigen Delivery Technologies (25/09/2009)
• New Approaches to Pharma R&D (21/09/2009)
• Osteoporosis (21/09/2009)
• Acute Leukemias (11/09/2009)
• The Cardiovascular Market (04/09/2009)

---